Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The FDA has given clearance to an investigational new drug application for TMP-301, a treatment for cocaine use disorders, according to the drug manufacturer.
The program has also been awarded a grant expected to total $5.3 million grant over the course of 2 years from the National Institute on Drug Abuse in support of the development of TMP-301, according to a press release from Tempero Bio.
Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders TMP-301 (formerly HTL0014242) is a potent, selective, and orally available mGluR5 negative allosteric modulator (NAM) candidate discovered by So.
/PRNewswire/ Tempero Bio has recently been awarded a grant expected to total $5.3 million over two years from the National Institute on Drug Abuse (NIDA),.